Skip to content

Basket

You currently have no items in your basket.

Total (excl. vat) £0.00
View basket & checkout
Antibodies

SARS-CoV-2 Spike RBD Nanobody

Product Sizes
50 ul
£469.00
CSB-RA33245A2GMY-50UL
100 ul
£782.00
CSB-RA33245A2GMY-100UL
About this Product
SKU:
CSB-RA33245A2GMY
Additional Names:
S, S1, S1-RBD, Spike glycoprotein
Application:
Block/Inhibit/Neutralise, Detection/Quantitation, ELISA
Buffer:
Preservative: 0.03% Proclin 300 Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
translate.label.attr.clone:
A1
Clonality:
Recombinant Monoclonal - Nanobody
Extra Details:
Recombinant anti-SARS-CoV-2 spike VHH is expressed from 293 cells (HEK293) with a human IgG1 Fc tag on C-terminal.
Immunogen:
Recombinant Human Novel Coronavirus Spike glycoprotein(S) (319-541aa) (CSB-YP3324GMY1 and CSB-MP3324GMY1b1)
Isotype:
IgG1
Physical State:
Liquid
Purification:
Affinity Purified
Reactivities:
Virus
Shipping Conditions:
Blue Ice
Storage Conditions:
-20[o]C/-70[o]C Avoid freeze/thaw cycles.
Supplier:
Cusabio
Type:
Antibody: Nanobodies
GICA In the Colloidal Gold Immunochromatography Assay detection system, the background of antibody (CSB-RA33245A2GMY) is clean, the detection limit can be as low as 25ng/ml (1.75ng/0.07ml), and the sensitivity is very good.
ELISA: Immobilize various types of SARS proteins at concentration of 2ug/ml on solid substrate, then react with SARS-CoV-2 Spike RBD Nanobody at concentration of 100ug/ml, 10ug/ml and 1ug/ml. It shows the SARS-CoV-2 Spike RBD Nanobody (CSB-RA33245A2GMY) is specific for SARS-CoV-2-S1-RBD protein, without any cross-reactivity with MERS-CoV, SARS-CoV, HCoV-OC43 or HCoV-229E.
Activity Assay- ELISA The Binding Activity of SARS-CoV-2 Spike RBD Nanobody with SARS-CoV-2-S1-RBD Activity: Measured by its binding ability in a functional ELISA. Immobilized SARS-CoV-2-S1-RBD (CSB-YP3324GMY1) at 2 ug/ml can bind SARS-CoV-2 Spike RBD Nanobody, the EC50 is 0.8674 ng/ml.
SARS-CoV-2 Spike protein RBD His/Sumostar Tag (CSB-YP3324GMY1) captured on COOH chip binding to the SARS-CoV-2 Spike RBD Nanobody (CSB-RA33245A2GMY), increases the local refractive index (RI), leading to a red shift of the LSPR peak position. The higher concentrations of SARS-CoV-2 Spike RBD Nanobody, the larger the wavelength shift. The detected affinity constant of SARS-CoV-2 Spike protein RBD/SARS-CoV-2 Spike RBD Nanobody binding is 28.2nM.
SARS-CoV-2 Spike RBD Nanobody (CSB-RA33245A2GMY) competed with ACE2-HRP conjugate (CSB-MP866317HU) for binding to SARS-CoV-2-S1-RBD (CSB-YP3324GMY1). The binding signal of SARS-CoV-2-S1-RBD and ACE2-HRP conjugate was gradually reduced as the SARS-CoV-2 Spike RBD Nanobody concentrations increased. It indicated that this SARS-CoV-2 Spike RBD Nanobody effectively inhibited the SARS-CoV-2-S1-RBD/ACE2 binding. And the IC50 of this SARS-CoV-2 Spike RBD Nanobody is 1.296 nM.